ʻOi aku ka Ozempic ʻoi aku ka maikaʻi o ka mālama ʻana i ka maʻi diabetes type 2

A HOLD Hoʻokuʻu ʻole 8 | eTurboNews | eTN
Avatar o Linda Hohnholz
i kakauia ma Linda Hohnholz

Ua hoʻolaha ʻo Novo Nordisk i kēia lā ua ʻae ka US Food and Drug Administration (FDA) i kahi 2 mg o ka Ozempic® (semaglutide) injection, kahi analog glucagon-like peptide-1 (GLP-1) i hoʻokahi pule i hōʻike ʻia me ka meaʻai a me ka hoʻoikaika kino. e hoʻomaikaʻi i ke kō koko i nā poʻe mākua me ka maʻi diabetes type 2 a e hōʻemi i ka pilikia o nā hanana cardiovascular nui e like me ka hōʻeha puʻuwai, ka hahau a i ʻole ka make i nā pākeke me ka maʻi maʻi type 2 a me ka maʻi puʻuwai ʻike ʻia. kōkua i ka poʻe e lilo i ke kaumaha. E loaʻa ana ʻo Ozempic® i ʻekolu mau lāʻau lapaʻau (2 mg, 0.5 mg, a me 1 mg) e kōkua i ka poʻe me ka maʻi maʻi type 2 e hoʻokō i kā lākou pahuhopu kō koko (A2C), i kēia manawa me ka poʻe me ka A1C kiʻekiʻe i hiki ʻole ke hoʻokō i kā lākou. A1C pahu hopu.

Ma ka Ozempic® SUSTAIN phase 3 clinical trial program, a hiki i ka 73% o ka poʻe me ka maʻi maʻi type 2 i mālama ʻia me Ozempic® 1 mg i hoʻohaʻahaʻa iho i ko lākou kō koko a hiki i ka pahuhopu ʻAmelika Diabetes Association o <7%.3-5 ʻOiai, aia nō. ʻaʻole i loaʻa i kā lākou koko koko.

"ʻO ka maʻi diabetes type 2 kahi maʻi paʻakikī e hiki ke holomua i ka manawa inā ke mālama nei ke kanaka me ka lāʻau lapaʻau, ka meaʻai a me ka hoʻoikaika kino," wahi a Dr Juan Pablo Frias, ka luna lapaʻau o Velocity Clinical Research, Los Angeles a me ka mea noiʻi nui o SUSTAIN FORTE, ka pae 3 hoʻokolohua lapaʻau e kākoʻo ana i ka ʻae ʻana o Ozempic® 2 mg. "Me kona palekana a me ka maikaʻi, kōkua ʻo Ozempic® i ka mālama ʻana i ka glucose koko a hāʻawi i ka hōʻemi nui o ka hanana cardiovascular i nā pākeke me ka maʻi maʻi type 2 a me ka maʻi puʻuwai ʻike ʻia, hiki ke kōkua i nā poʻe maʻi he nui ke kaumaha. Me ka 2 mg dose, loaʻa iā mākou kahi koho hou aʻe i hiki i nā poʻe maʻi ke noho i ka lāʻau lapaʻau like ʻole inā pono e hoʻololi ko lākou koko koko.

I ka hoʻāʻo ʻana ʻo SUSTAIN FORTE, loaʻa i ka poʻe me ka A1C hoʻomaka awelika o 8.9% i mālama ʻia me Ozempic® 2 mg i loaʻa i kahi hōʻemi koʻikoʻi a ʻoi aku ka maikaʻi o ke kō koko o 2.1% i ka pule 40 i hoʻohālikelike ʻia me 1.9% me Ozempic® 1 mg (P<0.01). ).1 Ma ka haʻawina hoʻokahi, ʻo nā kānaka me ka awelika hoʻomaka kaumaha o 219 lb i mālama ʻia me Ozempic® 2 mg i ʻike i ka pohō kaumaha o 14.1 lb i hoʻohālikelike ʻia me ka pohō kaumaha o 12.5 lb me Ozempic® 1 mg; ʻaʻole koʻikoʻi ka ʻokoʻa. No nā mea ʻelua o Ozempic®, ʻaʻohe hōʻailona palekana hou i ʻike ʻia. ).1

"Aia ʻo Ozempic® i ke poʻo o ke kōkua ʻana iā Novo Nordisk e hoʻololi i ka mālama maʻi diabetes, me ka ʻoi aku o hoʻokahi miliona mau kānaka me ka maʻi maʻi type 2 ma ʻAmelika Hui Pū ʻIa i mālama ʻia me Ozempic®," wahi a Doug Langa, ka hope pelekikena hoʻokō, nā hana a me ka pelekikena o ʻAmelika ʻĀkau. o Novo Nordisk Inc. "Me ka Ozempic® i loaʻa i kēia manawa i nā ʻano ikaika dosing, manaʻo mākou e hiki iā mākou ke kōkua i nā poʻe hou aʻe e noho ana me ka maʻi maʻi type 2 e koi ana i ka hoʻokele koko koko e ʻike i nā pono o Ozempic®."  

Manaʻo ʻo Novo Nordisk e hoʻomaka koke i ka Ozempic® 2 mg ma ʻAmelika Hui Pū ʻIa. Ua ʻae ʻia ʻo Ozempic® 2 mg e Swiss Medic i Kepakemapa 2021 a ukali ʻia e Health Canada a me ka European Medicines Agency i Ianuali 2022.

No ka mea kākau

Avatar o Linda Hohnholz

Linda Hohnholz

Lunahooponopono no eTurboNews ma ka eTN HQ.

kakau
E hoʻomaopopo i
malihini
0 Comments
Nā ʻōlelo Hoʻohui Kūʻai
E nānā i nā ʻōlelo āpau
0
E aloha nui i kou mau manaʻo, e ʻoluʻolu.x
()
x
Kaʻana like i...